Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT05653635
Recruiting Phase 2

Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study

NCT05653635 · tracked via the Priya Life Science France tracker
Sponsor
Centre Paul Strauss
Phase
Phase 2
Started
2026-03-01
Last updated
2026-02-04

Condition(s) studied

Glioblastoma

Investigational drug(s) / intervention(s)

Simultaneous-integrated boost with IMRT

Simultaneous-integrated boost with IMRT: Simultaneous-integrated boost guided by FDOPA-PET

Study summary

ReciDOPA is a phase II, single-stage randomized, multicenter, prospective trial assessing the efficacy of an irradiation protocol based on Intensity-modulated radiation therapy with simultaneous-integrated boost guided by FDOPA-PET in patient with recurrent glioblastoma.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age \> 18 years * Glioblastoma, World Health Organization (WHO) grade IV, histologically proven * Performance status 0, 1 or 2 * Neurological status ≥ 2 * Past irradiation in previsional re-irradiated site or in the vicinity (5 to 7 cm) * Radiological proven recurrence according to 1 and 2 criteria, Wen et al * Remaining node after partial surgery post-recurrence * 1 to 3 recurrence site(s) \< 35 mm in wide axis and separated by at least 5 mm * Volume of each lesion \< 35 mL * Distance between recurrence node(s) and optic nerves (left and right), chiasma and/or cerebral trunk \> 10 mm Exclusion Criteria: * Patient with contraindication to MRI or PET * Glioblastomatose * Pregnancy or breastfeeding * Patient that do not understand French * Patient without affiliation to the national or local social security * Patients not able to comply to the protocol assessments for geographic, social or psychological reasons * Minor or patients placed under guardianship or supervision * Patients deprived of liberty * Patients placed under judicial protection * Patients that are not able to express their consent

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
CHRU de Nancy Nancy De Not Yet Recruiting
Centre Paul Strauss Strasbourg France Recruiting

More Centre Paul Strauss trials in France

Interest of PET-MRI in the Evaluation of the Response After Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma Recruiting
Hippotherapy Teenager-pediatric Radiotherapy Recruiting
Prediction of Radiotherapy Efficacy in Patients With Triple-negative Breast Cancer Active, not recruiting
Study of Preoperative RAdiation Therapy With Concomitant Liposomal Transcrocetin (L-TC) in Soft tISsue Sarcomas Starting soon
Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma Recruiting

Other trials for the same condition

Surgery for Recurrent Glioblastoma Recruiting
AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma Active, not recruiting
A Study to Better Understand the Biological and Molecular Mechanisms Involved in Glioblastoma Recurrence and Progression Recruiting
Study of Prognostic Biomarkers of Survival at 6 Months for Patients Treated With Bevacizumab Glioblastomas in First Relapse After Failure of Radiochemotherapy Recruiting
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05653635 on ClinicalTrials.gov ↗ ← All trials in France